3//SEC Filing
BAY CITY CAPITAL LLC 3
Accession 0001104659-21-128639
CIK 0001840233other
Filed
Oct 20, 8:00 PM ET
Accepted
Oct 21, 8:49 PM ET
Size
7.8 KB
Accession
0001104659-21-128639
Insider Transaction Report
Form 3
BAY CITY CAPITAL LLC
10% Owner
Holdings
- (indirect: See footnotes)
Series C Preferred Stock
→ Common Stock (151,294 underlying) - (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (665,696 underlying)
Footnotes (4)
- [F1]The Series B Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
- [F2]The Series C Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
- [F3]Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co.
- [F4]Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.
Documents
Issuer
Xilio Therapeutics, Inc.
CIK 0001840233
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001288452
Filing Metadata
- Form type
- 3
- Filed
- Oct 20, 8:00 PM ET
- Accepted
- Oct 21, 8:49 PM ET
- Size
- 7.8 KB